Profile data is unavailable for this security.
About the company
Tyra Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. Its initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. Its lead product candidate, TYRA-300, is an investigational, oral, FGFR3-selective inhibitor being evaluated in an international, multi-center, open label Phase 1 clinical study, SURF301. Its second oncology product candidate, TYRA-200, is an investigational, oral, FGFR1/2/3 inhibitor with potency against activating FGFR2 gene alterations, and clinically important molecular brake and gatekeeper resistance mutations.
- Revenue in USD (TTM)0.00
- Net income in USD-69.13m
- Incorporated2018
- Employees49.00
- LocationTyra Biosciences Inc2656 State StreetCARLSBAD 92008United StatesUSA
- Phone+1 (619) 728-4760
- Fax+1 (302) 655-5049
- Websitehttps://tyra.bio/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viridian Therapeutics Inc | 314.00k | -237.73m | 881.39m | 96.00 | -- | 3.17 | -- | 2,806.97 | -5.32 | -5.32 | 0.007 | 8.19 | 0.0007 | -- | 3.08 | 3,340.43 | -51.37 | -55.59 | -54.93 | -60.32 | -- | -- | -75,711.47 | -5,678.12 | -- | -- | 0.0437 | -- | -82.28 | -48.16 | -83.05 | -- | 15.08 | -- |
| OPKO Health Inc | 863.49m | -188.86m | 885.18m | 3.93k | -- | 0.7069 | -- | 1.03 | -0.2513 | -0.2513 | 1.15 | 1.80 | 0.4133 | 7.80 | 6.89 | 219,718.60 | -9.03 | -7.14 | -10.03 | -8.14 | 36.84 | 34.42 | -21.86 | -13.83 | 1.22 | -15.24 | 0.1574 | -- | -14.01 | -2.70 | 42.49 | -- | -10.19 | -- |
| ARS Pharmaceuticals Inc | 30.00k | -54.37m | 904.02m | 24.00 | -- | 3.90 | -- | 30,134.16 | -0.5719 | -0.5719 | 0.0003 | 2.39 | 0.0001 | -- | -- | 1,250.00 | -21.13 | -20.37 | -21.45 | -21.32 | -- | -- | -181,216.70 | -17,491.75 | -- | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
| Bicycle Therapeutics PLC (ADR) | 26.98m | -180.66m | 918.81m | 284.00 | -- | 2.77 | -- | 34.06 | -5.13 | -5.13 | 0.7585 | 8.74 | 0.0536 | -- | 26.38 | 94,985.91 | -35.92 | -29.45 | -40.92 | -32.98 | -- | -- | -669.72 | -571.36 | -- | -- | 0.0764 | -- | 86.52 | 30.47 | -60.28 | -- | 19.82 | -- |
| Eyepoint Pharmaceuticals Inc | 46.02m | -70.80m | 939.60m | 121.00 | -- | 3.32 | -- | 20.42 | -1.84 | -1.84 | 1.18 | 5.43 | 0.1719 | 1.36 | 5.64 | 380,314.10 | -26.44 | -40.44 | -32.35 | -47.79 | 89.93 | 83.45 | -153.84 | -186.23 | 5.39 | -- | 0.00 | -- | 11.14 | -- | 30.77 | -- | -- | -- |
| BioCryst Pharmaceuticals Inc | 331.41m | -226.54m | 942.11m | 536.00 | -- | -- | -- | 2.84 | -1.18 | -1.18 | 1.72 | -2.21 | 0.6212 | 0.1658 | 6.16 | 618,306.00 | -42.46 | -47.95 | -55.84 | -64.89 | 98.59 | 97.06 | -68.36 | -114.94 | 3.12 | -1.11 | 2.19 | -- | 22.37 | 74.21 | 8.33 | -- | 42.73 | -- |
| Praxis Precision Medicines Inc | 2.45m | -123.28m | 943.67m | 82.00 | -- | 6.96 | -- | 385.64 | -23.64 | -23.64 | 0.3719 | 7.92 | 0.0241 | -- | -- | 29,841.46 | -121.41 | -74.04 | -161.17 | -85.12 | -- | -- | -5,037.88 | -24,589.25 | -- | -- | 0.00 | -- | -- | -- | 42.40 | -- | -4.52 | -- |
| Innoviva Inc | 310.46m | 179.72m | 952.16m | 112.00 | 6.79 | 1.43 | 4.42 | 3.07 | 2.24 | 2.24 | 3.96 | 10.66 | 0.2509 | 0.8825 | 4.19 | 2,771,991.00 | 14.52 | 26.24 | 15.62 | 28.53 | 86.27 | -- | 57.89 | 76.84 | 7.96 | -- | 0.398 | -- | -6.30 | 3.53 | -15.99 | -14.57 | -- | -- |
| Cassava Sciences Inc | 0.00 | -97.22m | 957.46m | 29.00 | -- | 6.80 | -- | -- | -2.32 | -2.32 | 0.00 | 3.25 | 0.00 | -- | -- | 0.00 | -50.31 | -30.74 | -53.23 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
| Tyra Biosciences Inc | 0.00 | -69.13m | 960.66m | 49.00 | -- | 3.85 | -- | -- | -1.62 | -1.62 | 0.00 | 4.75 | 0.00 | -- | -- | 0.00 | -28.10 | -- | -29.36 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.96 | -- | -- | -- |
| MacroGenics Inc | 58.75m | -9.06m | 972.82m | 339.00 | -- | 6.32 | 1,660.10 | 16.56 | -0.1525 | -0.1525 | 0.9462 | 2.46 | 0.203 | 6.15 | 1.76 | 173,300.90 | -3.13 | -37.76 | -3.82 | -45.53 | 86.00 | -- | -15.42 | -133.96 | 4.46 | -117.57 | 0.00 | -- | -61.33 | -0.4606 | 92.44 | -- | -41.13 | -- |
| Silence Therapeutics plc | 35.12m | -53.38m | 996.08m | 116.00 | -- | 37.05 | -- | 28.36 | -0.4905 | -0.4905 | 0.322 | 0.2159 | 0.2527 | -- | 94.73 | 302,771.50 | -38.40 | -43.18 | -47.88 | -53.35 | 54.24 | -- | -151.98 | -422.12 | -- | -15.11 | 0.0155 | -- | 40.97 | 305.31 | -2.74 | -- | 149.02 | -- |
| Petro Usa Inc | 0.00 | -33.38k | 1.00bn | -- | -- | -- | -- | -- | -0.0002 | -0.0002 | 0.00 | -0.0008 | 0.00 | -- | -- | -- | -19,074.29 | -192,120.00 | -- | -- | -- | -- | -- | -- | -- | -118.21 | -- | -- | -- | -- | -81.58 | -- | -- | -- |
| Liquidia Corp | 17.49m | -78.50m | 1.00bn | 136.00 | -- | 19.11 | -- | 57.26 | -1.21 | -1.21 | 0.2691 | 0.6891 | 0.1413 | -- | 3.85 | 128,588.20 | -63.43 | -55.02 | -71.31 | -62.69 | 83.49 | 82.18 | -448.89 | -474.59 | -- | -26.14 | 0.4942 | -- | 9.75 | 45.23 | -91.40 | -- | 66.93 | -- |
| Arcutis Biotherapeutics Inc | 59.61m | -262.14m | 1.02bn | 296.00 | -- | 9.65 | -- | 17.05 | -3.90 | -3.90 | 0.8602 | 0.9161 | 0.1508 | 0.483 | 3.48 | 201,371.60 | -66.31 | -65.64 | -74.24 | -71.72 | 91.63 | -- | -439.79 | -1,513.03 | 6.80 | -8.11 | 0.6947 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
Data as of May 02 2024. Currency figures normalised to Tyra Biosciences Inc's reporting currency: US Dollar USD
38.73%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 06 Feb 2024 | 10.42m | 19.83% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 2.77m | 5.27% |
| BVF Partners LPas of 31 Dec 2023 | 2.74m | 5.22% |
| Fairmount Funds Management LLCas of 31 Dec 2023 | 1.39m | 2.65% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 886.47k | 1.69% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 740.34k | 1.41% |
| JPMorgan Investment Management, Inc.as of 31 Dec 2023 | 364.06k | 0.69% |
| Perceptive Advisors LLCas of 31 Dec 2023 | 360.00k | 0.69% |
| Kynam Capital Management LPas of 31 Dec 2023 | 340.19k | 0.65% |
| Geode Capital Management LLCas of 31 Dec 2023 | 333.47k | 0.64% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
